Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.77 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.77 |
| ▸ | FBP1 | P09467 | 2/20 | 0.77 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.77 |
| ▸ | SLCO2B1 | O94956 | 2/20 | 0.77 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.77 |
| ▸ | MAPT | P10636 | 2/20 | 0.77 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.77 |
| ▸ | HPGD | P15428 | 2/20 | 0.77 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.77 |
| ▸ | APEX1 | P27695 | 2/20 | 0.77 |
| ▸ | DAPK1 | P53355 | 2/20 | 0.77 |
| ▸ | GLA | P06280 | 1/20 | 0.77 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.77 |
| ▸ | RAD52 | P43351 | 1/20 | 0.77 |
| ▸ | HSPE1 | P61604 | 1/20 | 0.77 |
| ▸ | TST | Q16762 | 1/20 | 0.77 |
| ▸ | CD38 | P28907 | 3/20 | 0.62 |
| ▸ | ABCC1 | P33527 | 2/20 | 0.62 |
| ▸ | RECQL | P46063 | 2/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12640014 | 1.00 | MEN1 (0.77) | MEN1KMT2AFBP1KDM4ESLCO2B1 | |
| Gossypetin SCHEMBL157033 | 0.87 | MEN1 (1.00) | MEN1KMT2AFBP1KDM4ESLCO2B1 | |
| Gossypetin SCHEMBL29929428 | 0.87 | MEN1 (1.00) | MEN1KMT2AFBP1KDM4ESLCO2B1 | |
| SCHEMBL12640012 | 0.87 | MAPT (0.61) | MEN1KMT2AFBP1KDM4ESLCO2B1 | |
| Gossypetin SCHEMBL29419067 | 0.87 | MEN1 (1.00) | MEN1KMT2AFBP1KDM4ESLCO2B1 | |
| SCHEMBL24314098 | 0.86 | MEN1 (0.59) | MEN1KMT2AFBP1KDM4ESLCO2B1 | |
| Gossypetin SCHEMBL16782915 | 0.86 | MEN1 (0.97) | MEN1KMT2AFBP1KDM4ESLCO2B1 | |
| Herbacetin SCHEMBL31442430 | 0.85 | FBP1 (1.00) | MEN1KMT2AFBP1KDM4ESLCO2B1 | |
| Herbacetin SCHEMBL872691 | 0.85 | FBP1 (1.00) | MEN1KMT2AFBP1KDM4ESLCO2B1 | |
| SCHEMBL1880963 | 0.85 | MEN1 (0.66) | MEN1KMT2AFBP1KDM4ESLCO2B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250295577-A1 | EXTRACT OF YOUNG FLOWERS AND COSMETIC USES | SOCIETE INDUSTRIELLE LIMOUSINE D'APPLICATION BIOLOGIQUE (FR) | 2025-09-25 | — | — | US | disclosed |
| US-20240307472-A1 | BEVERAGES CONTAINING NATURAL PRODUCTS | PK Beverages LLC (US) | 2024-09-19 | — | — | US | disclosed |
| WO-2024189588-A1 | BEVERAGES CONTAINING NATURAL PRODUCTS | KENNEDY J PHILLIP (US) | 2024-09-19 | — | — | WO | disclosed |
| EP-4401711-A1 | STABLE NON-AQUEOUS COMPOSITIONS OF FUNCTIONAL INGREDIENTS AND METHODS OF MAKING THE SAME | Nulixir Inc. (US) | 2024-07-24 | — | — | EP | disclosed |
| EP-4401714-A1 | ORAL COMPOSITIONS WITH PLANT MATTER EXTRACTS AND METHODS OF MAKING THE SAME | Nulixir Inc. (US) | 2024-07-24 | — | — | EP | disclosed |
| EP-4401712-A1 | ORAL COMPOSITIONS WITH IMPROVED BIOAVAILABILITY AND METHODS OF MAKING THE SAME | Nulixir Inc. (US) | 2024-07-24 | — | — | EP | disclosed |
| EP-4401713-A1 | ALIMENTARY-RELATED PARTICLES, PRODUCTION METHODS, AND PRODUCTION APPARATUS | Nulixir Inc. (US) | 2024-07-24 | — | — | EP | disclosed |
| US-20240165036-A1 | ENCAPSULATED VITAMIN D | Nulixir Inc. | 2024-05-23 | — | — | US | disclosed |
| US-20230404126-A1 | ENCAPSULATED PRECURSORS OF NICOTINAMIDE ADENINE DINUCLEOTIDE AND METHODS OF MAKING THE SAME | Nulixir Inc. | 2023-12-21 | — | — | US | disclosed |
| US-20230157973-A1 | ORAL COMPOSITIONS WITH PLANT MATTER EXTRACTS AND METHODS OF MAKING THE SAME | Nulixir Inc. | 2023-05-25 | — | — | US | disclosed |
| US-20230111238-A1 | STABLE COMPOSITIONS OF FUNCTIONAL INGREDIENTS AND METHODS OF MAKING THE SAME | Nulixir Inc. | 2023-04-13 | — | — | US | disclosed |
| US-20230111190-A1 | ORAL COMPOSITIONS WITH IMPROVED BIOAVAILABILITY AND METHODS OF MAKING THE SAME | Nulixir Inc. | 2023-04-13 | — | — | US | disclosed |
| US-20230111756-A1 | STABLE FORMULATIONS OF PLANTS EXTRACTS AND METHODS OF MAKING THE SAME | Nulixir Inc. | 2023-04-13 | — | — | US | disclosed |
| WO-2023043854-A1 | ALIMENTARY-RELATED PARTICLES, PRODUCTION METHODS, AND PRODUCTION APPARATUS | Nulixir Inc. (US) | 2023-03-23 | — | — | WO | disclosed |
| WO-2023043852-A1 | STABLE NON-AQUEOUS COMPOSITIONS OF FUNCTIONAL INGREDIENTS AND METHODS OF MAKING THE SAME | Nulixir Inc. (US) | 2023-03-23 | — | — | WO | disclosed |
| WO-2023043855-A1 | ORAL COMPOSITIONS WITH PLANT MATTER EXTRACTS AND METHODS OF MAKING THE SAME | Nulixir Inc. (US) | 2023-03-23 | — | — | WO | disclosed |
| WO-2023043853-A1 | ORAL COMPOSITIONS WITH IMPROVED BIOAVAILABILITY AND METHODS OF MAKING THE SAME | Nulixir Inc. (US) | 2023-03-23 | — | — | WO | disclosed |
| US-20230081296-A1 | STABLE NON-AQUEOUS COMPOSITIONS OF PLANTS EXTRACTS AND METHODS OF MAKING THE SAME | Nulixir Inc. | 2023-03-16 | — | — | US | disclosed |
| US-20230079480-A1 | STABLE NON-AQUEOUS COMPOSITIONS OF FUNCTIONAL INGREDIENTS AND METHODS OF MAKING THE SAME | Nulixir Inc. | 2023-03-16 | — | — | US | disclosed |
| US-20230082651-A1 | STABLE AQUEOUS COMPOSITIONS OF PLANTS EXTRACTS AND METHODS OF MAKING THE SAME | Nulixir Inc. | 2023-03-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240307472-A1 | BEVERAGES CONTAINING NATURAL PRODUCTS | FABP3, SIRT3, SIRT5 | MEN1 349/4885KMT2A 923/4885FBP1 312/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.